Who Optimizes SG&A Costs Better? Amgen Inc. or Walgreens Boots Alliance, Inc.

Optimizing SG&A Costs: Amgen Inc. vs. Walgreens Boots Alliance, Inc.

In the competitive landscape of corporate finance, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Amgen Inc. and Walgreens Boots Alliance, Inc. have showcased distinct strategies in optimizing these costs. Amgen Inc. maintained a relatively stable SG&A expense, averaging around $5.3 billion annually, with a notable increase of 31% from 2014 to 2023. In contrast, Walgreens Boots Alliance, Inc. exhibited a more substantial SG&A expenditure, averaging $23.6 billion annually, reflecting a 44% increase over the same period. This disparity highlights Walgreens' expansive operational scale compared to Amgen's more streamlined approach. Interestingly, 2024 data for Amgen is missing, suggesting potential strategic shifts or reporting delays. As businesses navigate economic challenges, understanding these cost management strategies offers valuable insights into corporate efficiency and financial health.